United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
Business Wire•20/10/2026•07:00 ET
0
Key Highlights
- ➤Third DPF facility opens in Houston to expand xenokidney and xenoheart manufacturing
- ➤Stewartville and Houston facilities designed to scale commercial production after product approvals
- ➤Clinical trials underway for UKidney, UThymoKidney, and UHeart xenotransplantation products
- ➤EXPAND trial transplanted United Therapeutics’ first xenokidney into an ESRD patient in 2025
Expert Statements
Martine Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics
“Every day, people with end-stage organ disease die waiting for an organ that never comes. With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them. It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality”
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
Named for Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, pioneers in xenotransplantation, the biosecure facility is purpose-built to manufacture United Therapeutics’ xenokidneys and xenohearts for its rapidly advancing xeno-organ manufacturing program
Get started
Create a free account to read the full story.